NEWCASTLE, AUSTRALIA – Tuesday 22 September 2020 – CannaPacific, an Australian biotechnology company focused on the cannabinoid pharmaceutical sector and Health House International have joined forces to be the first Australian companies to export medicinal cannabis products to South Africa successfully.
Utilising CannaPacific’s supply chain and Health House International’s import/export expertise, these leading Australian medicinal cannabis companies have led the way to open up this complex supply chain. Regulations surrounding inter-country movement of medicinal cannabis products are still evolving. Opening up the supply of export approved products for CannaPacific is a significant step forward for the Australian Industry.
“It’s great to see Australian companies working together to build an export supply chain for medicinal cannabis products and competing on a global scale,” said CannaPacific CEO, Josh Dennis.
Pharmacist and Health House International COO Paul Mavor, the first licensed importer of Canadian medicinal cannabis in May 2017, said “This shipment is the first export of Australian cannabis to Africa. It is a really significant step in cementing Australia’s place as a global supplier of pharmaceutical-grade medicinal cannabis. Projections are for Australian medical patients to hit 300,000 over the next few years, and the export market offers huge potential.”
CannaPacific is an Australian biotechnology company focused on the cannabinoid pharmaceutical sector. By combining advanced molecular breeding technology with a traditional approach to drug development, CannaPacific seeks to build a global therapeutic offering with an initial focus on palliative care and post-traumatic stress disorder.
CannaPacific’s strategy is to attain a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.
CannaPacific operates a full cGMP Medicinal Cannabis Supply Chain which is underpinned by a licenced cultivation facility nestled in the beautiful Byron Bay hinterland in northern NSW. The production facility includes a 10,000 sqm Dutch glasshouse and high-security outdoor cultivation area.
About medicinal cannabis:
Governments at both Commonwealth and State and Territory levels have implemented legislative and policy change to allow the cultivation, manufacture, prescribing and dispensing of medicinal cannabis products for patients in Australia. https://www.tga.gov.au/medicinal-cannabis-guidance-documents